DOCSLIB.ORG

Cefradine JNT Capsules PIL V4P2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cefradine JNT Capsules PIL V4P2 CP.CFR.JNT.C.FT.V4P2 PATIENT INFORMATION LEAFLET You should take this leaflet and any remaining MHRA Yellow Card in the Google Play or capsules with you to show the doctor. Apple App Store. By reporting side effects CEFRADINE 250mg AND 500mg CAPSULES you can help provide more information on the If you forget to take Cefradine safety of this medicine. Do not take a double dose to make up for a Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. forgotten capsule. • Keep this leaflet. You may need to read it again. 5. HOW TO STORE CEFRADINE • If you have further questions, please ask your doctor or your pharmacist. If you stop taking Cefradine • This medicine has been prescribed for you only. Do not pass it to others. It may harm Keep taking this medicine until it is finished or Do not use this medicine after the expiry date them even if their signs of illness are the same as yours. your doctor tells you to stop. Do not stop Pharma code shown on the pack your medicine came in. • If you get any of the side effects, talk to your doctor or pharmacist. This includes any Location taking it just because you feel better. Do not store above 25ºC. possible side effects not listed in this leaflet. See section 4. KEEP OUT OF THE SIGHT AND REACH OF If you have any further questions on the use CHILDREN. WHAT IS IN THIS LEAFLET of this medicine, ask your doctor, pharmacist 1. What Cefradine is and what it is used for Medicines should not be disposed of via or nurse. 2. What you need to know before you take Cefradine wastewater or household waste. Ask your 3. How to take Cefradine pharmacist how to dispose of medicines no 4. Possible side effects longer required. These measures will help to 5. How to store Cefradine 4. POSSIBLE SIDE EFFECTS protect the environment. 6. Contents of the pack and other information Cefradine Capsules contain lactose, which Like all medicines, this medicine can cause CONTENTS OF THE PACK AND WHAT CEFRADINE IS AND WHAT is a type of sugar. If you have been told by side effects, although not everyone gets 6. OTHER INFORMATION 1. IT IS USED FOR your doctor that you have an intolerance to them. some sugars, contact your doctor before Cefradine is an antibiotic and belongs to a What Cefradine Capsules contain taking this medicinal product. STOP taking Cefradine capsules and tell The active substance in your medicine is family of medicines called cephalosporins. your doctor immediately if you experience Cefradine capsules are used to treat a wide cefradine anhydrous. Each capsule contains Other medicines and Cefradine any of the following side effects: either 250mg or 500mg of cefradine. range of bacterial infections including: Check with your doctor or pharmacist if you • severe, possibly bloody diarrhoea • tonsillitis The capsules also contain the following are taking, or have recently taken any other • severe peeling or blistering of the skin inactive ingredients: magnesium stearate • sinusitis medicines even those not prescribed by a • swelling of the face, lips and tongue, • pharyngitis (E572), lactose monohydrate, titanium dioxide doctor. In particular tell your doctor if you are tightness of the chest and difficulty (E171) and indigo carmine (E132). The • laryngo-tracheo bronchitis taking any of the following: breathing, feeling faint or itchy skin. These • ear infections (otitis media) 250mg capsule also contains yellow iron • diuretics or ‘water tablets’ e.g. furosemide may be signs of an allergic reaction. oxide (E172) and erythrosin (E127). • chest infections (bronchitis or pneumonia) • probenecid (used to treat gout) • skin infections Other possible side effects: • bladder, urethra (the tube which carries What Cefradine Capsules look like and Driving and using machines Rare: may affect up to 1 in 1,000 people contents of the pack urine from the bladder) and kidney Cefradine Capsules do not usually affect your • vomiting (being sick) infections The 250mg strength capsules are blue and ability to drive, but if you experience any • headache orange in colour. dizziness do not drive or operate machinery. • abdominal pain It is also used in the prevention of infections The 500mg strength capsules are light blue in colour. following surgical procedures associated with Not known: frequency cannot be a high risk of infection. estimated from the available data HOW TO TAKE CEFRADINE Cefradine 250mg and 500mg Capsules are 280 C 3. • nausea (feeling sick) supplied in packs of 10, 20 or 100 capsules. WHAT YOU NEED TO KNOW Blue Pantone • diarrhoea and stomach pain Not all pack sizes may be marketed. 2. BEFORE YOU TAKE CEFRADINE Always take this medicine exactly as your • skin rashes Colours doctor or pharmacist has told you. Check with • confusion Manufacturer Do not take Cefradine Capsules if you: your doctor or pharmacist if you are not sure. • dizziness • are allergic to cefradine or any of the Facta Farmaceutici S.p.A., Via Laurentina Km • difficulty sleeping 24, 730, 00040 Pomezia, Roma, Italy. ingredients contained in this medicine; see DOSAGE • nervousness section 6 Contents of the pack and other • hyperactivity Marketing Authorisation Holder information. Adults (including the elderly) • thrush Athlone Pharmaceuticals Limited, • are allergic to penicillin antibiotics The recommended dose is 250mg or 500mg • heartburn, tightness in the chest Ballymurray, Co. Roscommon, Ireland. • suffer with rare hereditary problems of 4 times a day or 500mg-1000mg 2 times a • vaginal infection galactose intolerance, the Lapp lactase day. • stiffness and joint pain Distributor deficiency or glucose-galactose If you are elderly your doctor will see you (MAT) AWG • fever Kent Pharmaceuticals Limited, Repton Road, malabsorption more often while you are taking this medicine. • kidney inflammation, which could cause Measham, DE12 7DT, U.K. reduced urine output, cloudy or bloody Warnings and precautions Use in Children urine, swelling and pain PL 30464/0086 and PL 30464/0087 Talk to your doctor or pharmacist before If you are giving Cefradine Capsules to your • temporary liver problems which could taking cefradine if: child, your doctor will work out the right dose cause dark urine, pale stools, fever, This leaflet was last revised December 2018 Designer: • you suffer from kidney problems, as you depending on your child’s weight. yellowing of your eyes and skin may require a lower dose than normal The recommended dose is 25mg to 50mg/kg • temporary blood disorders which could 2 11/12/2018 • you are a diabetic. If you use chemical body weight daily in divided doses. cause you to have more infections than tests to check for sugar in urine, cefradine usual and can also make your skin pale may cause a false positive reaction. This The capsules should be swallowed whole and cause weakness, breathlessness and does not occur with dipstick type tests, or with a glass of water and can be taken before tiredness 140mm x 290mm tests for blood sugar. or after meals. However, if you find that this CP.CFR.JNT.C.FT.V3P1 • sore tongue or mouth CP.CFR.JNT.C.FT.V4P2 • you have an intolerance to some sugars as medicine upsets your stomach it may help to FT Cefradine 250mg & 500mg Capsules this medicine contains lactose. take it with food. If you notice any side effects not mentioned in this leaflet, or if you suffer from any of the Pregnancy, breast-feeding and fertility If you forget to take Cefradine Keep taking your medicine until the course is side effects listed please inform your doctor Talk to your doctor before taking Cefradine or pharmacist. Capsules if you are pregnant, think you may finished. If you forget to take a dose, take a Product: Customer: update in line with Reference Product PIL Supersedes: be pregnant, are planning to become dose as soon as you remember. Dimensions: Item Code: Proof No and Date: Revision: pregnant or are breast-feeding. Reporting of side effects If you take more Cefradine than you If you get any side effects, talk to your doctor or pharmacist. This includes any possible Important information about some of the should If you take more capsules than you should, side effects not listed in this leaflet. You can ingredients in this medicine contact your nearest hospital casualty also report side effects directly via the Yellow department or doctor immediately. Card Scheme website: www.mhra.gov.uk/yellowcard or search for CP.CFR.JNT.C.FT.V4P2.
Load more

Recommended publications
  • Prevalence of Self-Medication of Antibiotics Among People In
    International Journal of Pharmacy Teaching & Practices 2013, Vol.4, Issue 1, 504-510. Prevalence of self-medication of antibiotics among people in Bangladesh Nishat Chowdhury*, Mohammad Rashedul Islam, Md. Mehedi Hasan, Md. Mahmudur Rouf *Department of Pharmacy, State University of Bangladesh, Dhanmondi, Dhaka, Bangladesh Introduction Research Article Widespread and inappropriate use of antibiotics increases health care costs (1) and contributes to Please cite this paper as: Nishat Chowdhury*, Mohammad Rashedul Islam, Md. Mehedi Hasan, Md. Mahmudur Rouf. Prevalence of self- antibiotic resistance (2)。 Antimicrobial medication medication of antibiotics among people in Bangladesh . IJPTP, 2013, management in Bangladesh has been highlighted by 4(1), 504-510. previous studies as an area for improvement (3). Corresponding Author: There is already enough evidence of growing resistance to antimicrobials in this country resulting Nishat Chowdhury, from misuse (4-6). Previous study showed that Department of Pharmacy, State University of Bangladesh, antimicrobials are widely available (18% incidents) in Dhanmondi, Dhaka, Bangladesh the home medicine cabinets of the Dhaka City Telephone -88028612992, population (7). Since there is no prescription-only Email: [email protected] drug in Bangladesh, people can purchase drugs like sedatives, antimicrobials without prescription even in the remote parts of the country (8-9). The relative Abstract lack of data on the morbidity and mortality attributable to antibiotic resistance, including the This study attempts to investigate the prevalence of self- economic impact on individuals as well as on health medication of antibiotics among people in Bangladesh.This care and societies, may explain the weak reaction study was conducted in six districts of Bangladesh (Dhaka, from politicians, public health workers, and Munshiganj, Kishoreganj, Chittagong, Chandpur, Kushtia) by consumers to this threat to public health (10).
    [Show full text]
  • Consideration of Antibacterial Medicines As Part Of
    Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee on Selection and Use of Essential Medicines (see The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO: https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1) and Corrigenda (March 2020) – TRS1021 (https://www.who.int/medicines/publications/essentialmedicines/TRS1021_corrigenda_March2020. pdf?ua=1). Executive summary of the report: https://apps.who.int/iris/bitstream/handle/10665/325773/WHO- MVP-EMP-IAU-2019.05-eng.pdf?ua=1.
    [Show full text]
  • 2012 Harmonized Tariff Schedule Pharmaceuticals Appendix
    Harmonized Tariff Schedule of the United States (2014) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2014) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACEVALTRATE 25161-41-5 ABAFUNGIN 129639-79-8 ACEXAMIC ACID 57-08-9 ABAGOVOMAB 792921-10-9 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABAPERIDONE 183849-43-6 ACITAZANOLAST 114607-46-4 ABARELIX 183552-38-7 ACITEMATE 101197-99-3 ABATACEPT 332348-12-6 ACITRETIN 55079-83-9 ABCIXIMAB 143653-53-6 ACIVICIN 42228-92-2 ABECARNIL 111841-85-1 ACLANTATE 39633-62-0 ABETIMUS 167362-48-3 ACLARUBICIN 57576-44-0 ABIRATERONE 154229-19-3 ACLATONIUM NAPADISILATE 55077-30-0 ABITESARTAN 137882-98-5 ACLIDINIUM BROMIDE 320345-99-1 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURIN 178535-93-8 ACOLBIFENE 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDE 185106-16-5
    [Show full text]
  • Cefotaxime: Rate of Bacterial Killing and Interactions with Serum and Leukocyte Activity
    ACTA M~DICA PORTUGUESA 1983; 4: 167-171 ORIGINAL CEFOTAXIME: RATE OF BACTERIAL KILLING AND INTERACTIONS WITH SERUM AND LEUKOCYTE ACTIVITY GIULIANA GIALDRONI GRASSI, PATRIZIA MANGIAROTTI, ANNA FIETTA Chair of Chemotherapy. Istituto Forlanini. University of Pavia. Italy SUMMARY Cefotaxime (HR 756) was compared with cefazolin and cephaloridine with regard to the rate of bacterial killing and to the influence on the bactericidal activity of human serum and polyrnorphonuclear leukocytes. At concentrations equal to 1-2 x MIC cefotaxime showed a more rapid and complete bactericidal activity on E. coil K 12 than cephaloridine and cefazolin. In presence of the latters in fact, bacterial regrowth was observed after 24 hours. On S. aureus a complete killing activity of cefotaxime appeared at concentrations of 8 x MIC. A synergism seemed to exist between the complement dependent bactericidal activity of normal human serum and cephalosporins. E. coil K 12 (a rough strain) was killed by the combi nation of human serum and both cefotaxime and cefazolin at concentrations that were not bactericidal by themselves. Cephaloridine on the contrary showed an additive activity with normal human serum. Finally evidence that cefotaxime enhanced the bactericidal activity of human polymorphonuclear leukocytes against S. faecaiis, is reported. RESUMO Cefotaxirna: Poder Bactericida e Interaccao corn a Actividade Leucocitãria e do Soro. Cornparou-se o poder bactericida e a interferência da cefotaxima (HR 756) na actividade bactericida dos leucocitos polimorfonucleares e do soro corn os parametros equivalentes referentes a cefazolina e a cefaloridina. A concentracOes equivalentes a 1-2 vezes a concentracao Inibitória Minima (CIM) a cefotaxima revelou uma accAo bactericida mais rápida e completa sobre o E.
    [Show full text]
  • Analysis of Cephalosporins on a Polar Endcapped C18 3 Um Particle
    Application Note 20672 Note Application Analysis of Cephalosporins on a Polar Endcapped C18 3 µm Particle Column Valeria Barattini, Thermo Fisher Scientific, Runcorn, Cheshire, UK Key Words Syncronis, aQ, cephalosporins, polar endcapping, antibiotics Abstract The analysis of species containing polar groups using reversed phase HPLC can be challenging. The polar groups present on the analytes can result in secondary interactions with silanols on the silica surface. Furthermore, the overall polarity of the molecule sometimes calls for the use of mobile phases with very high aqueous content to ensure the analyte solubility, retention and elution, at the expense of stationary phase stability. In this application note we demonstrate the analysis of a mix of four analytes from the cephalosporin antibiotics family on a Thermo Scientific™ Syncronis™ aQ 3 µm particle column. The analysis yields excellent peak shape and resolution in short run times, as well as outstanding reproducibility. Introduction One of the key goals for the chromatographer is to achieve a consistent, reproducible separation. The selection of a highly reproducible HPLC column is essential if this goal is to be attained. The Syncronis column range has been engineered to provide exceptional A group of four cephalosporins, listed in Figure 2, was reproducibility due to its highly pure, high surface area chosen to be separated using a Syncronis aQ column with silica, dense bonding and double endcapping, all a 3 µm particle. Two of the components (cephalexin and controlled and characterized through the use of rigorous cefradin) differ only in the presence of a phenyl group in testing. The aQ phase endcapping group has been further chephalexin compared to a 1,4-cyclohexadiene in optimized to provide a controlled interaction mechanism cefradine.
    [Show full text]
  • European Surveillance of Healthcare-Associated Infections in Intensive Care Units
    TECHNICAL DOCUMENT European surveillance of healthcare-associated infections in intensive care units HAI-Net ICU protocol Protocol version 1.02 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT European surveillance of healthcare- associated infections in intensive care units HAI-Net ICU protocol, version 1.02 This technical document of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Carl Suetens. In accordance with the Staff Regulations for Officials and Conditions of Employment of Other Servants of the European Union and the ECDC Independence Policy, ECDC staff members shall not, in the performance of their duties, deal with a matter in which, directly or indirectly, they have any personal interest such as to impair their independence. This is version 1.02 of the HAI-Net ICU protocol. Differences between versions 1.01 (December 2010) and 1.02 are purely editorial. Suggested citation: European Centre for Disease Prevention and Control. European surveillance of healthcare- associated infections in intensive care units – HAI-Net ICU protocol, version 1.02. Stockholm: ECDC; 2015. Stockholm, March 2015 ISBN 978-92-9193-627-4 doi 10.2900/371526 Catalogue number TQ-04-15-186-EN-N © European Centre for Disease Prevention and Control, 2015 Reproduction is authorised, provided the source is acknowledged. TECHNICAL DOCUMENT HAI-Net ICU protocol, version 1.02 Table of contents Abbreviations ...............................................................................................................................................
    [Show full text]
  • A Survey of Measures Used for the Prevention of Postoperative
    Eye (2008) 22, 620–627 & 2008 Nature Publishing Group All rights reserved 0950-222X/08 $30.00 www.nature.com/eye CLINICAL STUDY A survey of P Gordon-Bennett, A Karas, D Flanagan, C Stephenson and M Hingorani measures used for the prevention of postoperative endophthalmitis after cataract surgery in the United Kingdom Abstract used a neomycin eyedrop for postoperative prophylaxis. Purpose This study investigates the current Eye (2008) 22, 620–627; doi:10.1038/sj.eye.6702675; practice of United Kingdom (UK) published online 15 December 2006 ophthalmologists in perioperative antibiotic and antiseptic use in cataract surgery. Keywords: antibiotic; cataract surgery; Materials and methods A telephone postoperative endophthalmitis; prevention; interview survey was conducted with prophylaxis ophthalmic staff at all ophthalmic training units in the UK in October and November 2005. Results The practices of a total of 800 Introduction Department of consultants were ascertained. Preoperatively, Ophthalmology, 795 (99.4%) surgeons used povidone-iodine to There is widespread variation in the prophylactic measures used to prevent Hinchingbrooke Hospital, prepare the skin. In all, 558 (69.8%) instilled Huntingdon, endophthalmitis following cataract surgery1 but 5 or 10% povidone-iodine in the conjunctival Cambridgeshire, UK in the light of rising endophthalmitis incidence sac; 47 (5.9%) gave preoperative antibiotic rates2,3 and new scientific evidence, a eyedrops. Intraoperatively, intracameral Correspondence: P Gordon- reassessment of methods is required. Although Bennett, antibiotics were given either as a bolus rare, endophthalmitis carries a devastating Department of [80 (10.0%) intracameral cefuroxime, 29 (3.6%) Ophthalmology, prognosis, with only 33% of patients achieving intracameral vancomycin] or in the irrigating Hinchingbrooke Hospital, visual acuity better than 6/12.4 Establishing Huntingdon, fluid [33 (4.1%) vancomycin].
    [Show full text]
  • The New Fifth-Generation Cephalosporins – a Balance Between Safety and Efficacy
    REVIEWS Ref: Ro J Pharm Pract. 2020;13(3) DOI: 10.37897/RJPhP.2020.3.2 The new fifth-generation cephalosporins – a balance between safety and efficacy Aura Rusu1, Ioana-Andreea Lungu2 1 Pharmaceutical and Therapeutical Chemistry Department, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mures, Romania 2 Doctoral School of Medicine and Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mures, Romania Abstract Cephalosporins are beta-lactam antibiotics classified into five generations. The newest generation has three representa- tives: ceftaroline fosamile, the combination ceftolozane/tazobactam (cephalosporin/beta-lactamase inhibitor), and ceftobi- prole medocaril. These new cephalosporins are valuable anti-infective agents, with potent activity against multidrug-re- sistant bacteria, and with a positive balance between benefits and side effects. However, the fifth-generation cephalosporins should be judiciously used to prevent the occurrence of bacterial resistance phenomenon. Keywords: cephalosporins, ceftaroline, ceftolozane, ceftobiprole, MRSA, community-acquired pneumonia, complicated skin and soft tissue infections INTRODUCTION emerged as a result of increased only, in the situation where other Cephalosporins (CFs) are beta- bacterial resistance to classical antibacterial drugs were not lactam antibiotics with numerous antibiotics. Based on the efficient. representatives widely used in the antimicrobial activity, the CFs are therapy
    [Show full text]
  • Antibiotic Classes
    Penicillins Aminoglycosides Generic Brand Name Generic Brand Name Amoxicillin Amoxil, Polymox, Trimox, Wymox Amikacin Amikin Ampicillin Omnipen, Polycillin, Polycillin-N, Gentamicin Garamycin, G-Mycin, Jenamicin Principen, Totacillin, Unasyn Kanamycin Kantrex Bacampicillin Spectrobid Neomycin Mycifradin, Myciguent Carbenicillin Geocillin, Geopen Netilmicin Netromycin Cloxacillin Cloxapen Paromomycin Dicloxacillin Dynapen, Dycill, Pathocil Streptomycin Flucloxacillin Flopen, Floxapen, Staphcillin Tobramycin Nebcin Mezlocillin Mezlin Nafcillin Nafcil, Nallpen, Unipen Quinolones Oxacillin Bactocill, Prostaphlin Generic Brand Name Penicillin G Bicillin L-A, First Generation Crysticillin 300 A.S., Pentids, Flumequine Flubactin Permapen, Pfizerpen, Pfizerpen- Nalidixic acid NegGam, Wintomylon AS, Wycillin Oxolinic acid Uroxin Penicillin V Beepen-VK, Betapen-VK, Piromidic acid Panacid Ledercillin VK, V-Cillin K Pipemidic acid Dolcol Piperacillin Pipracil, Zosyn Rosoxacin Eradacil Pivampicillin Second Generation Pivmecillinam Ciprofloxacin Cipro, Cipro XR, Ciprobay, Ciproxin Ticarcillin Ticar Enoxacin Enroxil, Penetrex Lomefloxacin Maxaquin Monobactams Nadifloxacin Acuatim, Nadoxin, Nadixa Generic Brand Name Norfloxacin Lexinor, Noroxin, Quinabic, Aztreonam Azactam, Cayston Janacin Ofloxacin Floxin, Oxaldin, Tarivid Carbapenems Pefloxacin Peflacine Generic Brand Name Rufloxacin Uroflox Imipenem, Primaxin Third Generation Imipenem/cilastatin Balofloxacin Baloxin Doripenem Doribax Gatifloxacin Tequin, Zymar Meropenem Merrem Grepafloxacin Raxar Ertapenem
    [Show full text]
  • Guidelines on Urological Infections
    Guidelines on Urological Infections M. Grabe (Chairman), T.E. Bjerklund-Johansen, H. Botto, M. Çek, K.G. Naber, P. Tenke, F. Wagenlehner © European Association of Urology 2010 TABLE OF CONTENTS PAGE 1. INTRODUCTION 7 1.1 Pathogenesis of urinary tract infections 7 1.2 Microbiological and other laboratory findings 7 1.3 Classification of urological infections 8 1.4 Aim of guidelines 8 1.5 Methods 9 1.6 Level of evidence and grade of guideline recommendations 9 1.7 References 9 2. UNCOMPLICATED URINARY TRACT INFECTIONS IN ADULTS 11 2.1 Definition 11 2.1.1 Aetiological spectrum 11 2.2 Acute uncomplicated cystitis in premenopausal, non-pregnant women 11 2.2.1 Diagnosis 11 2.2.1.1 Clinical diagnosis 11 2.2.1.2 Laboratory diagnosis 11 2.2.2 Therapy 11 2.2.3 Follow up 12 2.3 Acute uncomplicated pyelonephritis in premenopausal, non-pregnant women 12 2.3.1 Diagnosis 12 2.3.1.1 Clinical diagnosis 12 2.3.1.2 Laboratory diagnosis 12 2.3.1.3 Imaging diagnosis 13 2.3.2 Therapy 13 2.3.2.1 Mild and moderate cases of acute uncomplicated pyelonephritis 13 2.3.2.2 Severe cases of acute uncomplicated pyelonephritis 13 2.3.3 Follow-up 14 2.4 Recurrent (uncomplicated) UTIs in women 16 2.4.1 Diagnosis 16 2.4.2 Prevention 16 2.4.2.1 Antimicrobial prophylaxis 16 2.4.2.2 Immunoactive prophylaxis 16 2.4.2.3 Prophylaxis with probiotics 17 2.4.2.4 Prophylaxis with cranberry 17 2.5 Urinary tract infections in pregnancy 17 2.5.1 Definition of significant bacteriuria 17 2.5.2 Screening 17 2.5.3 Treatment of asymptomatic bacteriuria 17 2.5.4 Duration of therapy 18 2.5.5 Follow-up 18 2.5.6 Prophylaxis 18 2.5.7 Treatment of pyelonephritis 18 2.5.8 Complicated UTI 18 2.6 UTIs in postmenopausal women 18 2.6.1 Risk factors 18 2.6.2 Diagnosis 18 2.6.3 Treatment 18 2.7 Acute uncomplicated UTIs in young men 19 2.7.1 Men with acute uncomplicated UTI 19 2.7.2 Men with UTI and concomitant prostate infection 19 2.8 Asymptomatic bacteriuria 19 2.8.1 Diagnosis 19 2.8.2 Screening 19 2.9 References 26 3.
    [Show full text]
  • Antibiotic Resistance Pattern Shown by Various Pathogens, Causing Infections in Neonates
    Antibiotic resistance pattern shown by various pathogens, causing infections in neonates Zaib Ali Shaheryar1*, Zaka ur Rehman1, Muhammad Zaman1, Shahid Shah2, Kashif Ur Rahman Khan3, Sajid Mahmood Khan4, Muhammad Wahab Amjad5, Maria Abdul Ghafoor Raja5 and Awais Ali Zaidi1 1Faculty of Pharmacy, The University of Lahore, Lahore, Pakistan 2Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan 3Institute of Pharmaceutical Sciences, University of Veterinary and Animal Sciences, Lahore, Pakistan 4Faculty of Pharmacy and Alternative Medicine, Islamia University, Bahawalpur, Pakistan 5Faculty of Pharmacy, Northern Border University, Arar, Saudi Arabia Abstract: This study was schemed to comprehend the latest kaleidoscopic trends of bacterial resistance in neonatal pathogens against all those antibiotics commonly employed as empirical therapy in neonates. The methodological approach included; isolation and subsequent identification of those pathogens having caused bacterial infections in neonates, application of antibiotic sensitivity testing and finally construing the conclusion depicting patterns of antibiotic resistance by various pathogens, isolated from neonatal biological samples. Antibiotic resistance patterns was evident in gram-positive as well as in gram-negative bacteria in all the eight species identified in this study. Even antibiotic drugs which are being commonly relied upon for treating multi-resistant bacterial infections, found to be in effective against many
    [Show full text]
  • Statistical Analysis Plan / Data Specifications the Risk of Acute Liver Injury Associated with the Use of Antibiotics. a Replica
    WP6 validation on methods involving an extended audience Statistical analysis plan / data specifications The risk of acute liver injury associated with the use of antibiotics. A replication study in the Utrecht Patient Oriented Database Version: July 11, 2013 Authors: Renate Udo, Marie L De Bruin Reviewers: Work package 6 members (David Irvine, Stephany Tcherny-Lessenot) 1 1. Context The study described in this protocol is performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium). The overall objective of PROTECT is to strengthen the monitoring of the benefit-risk of medicines in Europe. Work package 6 “validation on methods involving an extended audience” aims to test the transferability/feasibility of methods developed in other WPs (in particular WP2 and WP5) in a range of data sources owned or managed by Consortium Partners or members of the Extended Audience. The specific aims of this study within WP6 are: to evaluate the external validity of the study protocol on the risk of acute liver injury associated with the use of antibiotics by replicating the study protocol in another database, to study the impact of case validation on the effect estimate for the association between antibiotic exposure and acute liver injury. Of the selected drug-adverse event pairs selected in PROTECT, this study will concentrate on the association between antibiotic use and acute liver injury. On this topic, two sub-studies are performed: a descriptive/outcome validation study and an association study. The descriptive/outcome validation study has been conducted within the Utrecht Patient Oriented Database (UPOD).
    [Show full text]